Call toll-free 800.328.1267
The S&P 500 is pushing to new highs, but cannabis stocks aren't so lucky. Well known names like Canopy Growth (CGC), Cronos (CRON) and Aurora Cannabis (ACB) are down at least 4 percent so far today. The industry-tracking Alternative Harvest ETF (MJ) is also on...
Sentiment has swung sharply bearish this week. President Trump's tariffs on China are a big part of the story, but health care's another major culprit. The biggest decliner in the S&P 500 today, for instance, was Mylan (MYL). Disappointing results, manufacturing...
Health care stocks got slammed yesterday amid an apparent rotation away from "safe havens." The SPDR Health Care ETF (XLV) dropped 2.05 percent to its lowest price since January 30. While not that might not sound huge, it was the biggest drop relative to the broader...
Cannabis stocks have been on fire since last summer, and the buzz continued today as a major financier joined the industry. Early leader Tilray (TLRY) might have fallen asleep after a blistering rally in September, but others have lit up more recently. Aurora Cannabis...
Market Insights has covered the split between the new winners and losers in technology. Something similar seems to be underway in the health-care sector. Drug makers whose products offer the promise of growth have led. These includes biotechnology stocks, which keep...
A hospital company drowning in liabilities just reported good results. Now a trader is using options to position for a comeback. Here's a breakdown of the strategy detected yesterday afternoon in Community Health (CYH): 20,000 September 4 puts were sold for...
Something unusual is happening with prices, and it's become good news for certain companies this year. Inflation data from the government shows the price of services rose 2.7 percent year over year in January, while commodities had their first drop since November...
Initial public offerings have faced a double-whammy of challenges, but now experts expect a pickup. First, the stock market ended 2019 with its worst quarterly drop in over seven years. Volatility like that is a challenge for any company going public, but it was...
Biotechnology stocks are ripping in 2019, fueled by some high-profile takeovers. It was only the second trading session of the year that Bristol Myers Squibb (BMY) gobbled up Celgene (CELG) in a record $74 billion deal. Loxo Oncology (LOXO) accepted an $8 billion bid...